Clinical Trial Update: Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a planned first-line treatment for advanced gastric cancer using Fruquintinib in combination with a PD-1 inhibitor (tislelizum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Gastric (Stomach) Cancer, Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING